SEXUALLY TRANSMITTED DISEASES Introduction
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Oral Lichen Planus: a Case Report and Review of Literature
Journal of the American Osteopathic College of Dermatology Volume 10, Number 1 SPONSORS: ',/"!,0!4(/,/'9,!"/2!4/29s-%$)#)3 March 2008 34)%&%,,!"/2!4/2)%3s#/,,!'%.%8 www.aocd.org Journal of the American Osteopathic College of Dermatology 2007-2008 Officers President: Jay Gottlieb, DO President Elect: Donald Tillman, DO Journal of the First Vice President: Marc Epstein, DO Second Vice President: Leslie Kramer, DO Third Vice President: Bradley Glick, DO American Secretary-Treasurer: Jere Mammino, DO (2007-2010) Immediate Past President: Bill Way, DO Trustees: James Towry, DO (2006-2008) Osteopathic Mark Kuriata, DO (2007-2010) Karen Neubauer, DO (2006-2008) College of David Grice, DO (2007-2010) Dermatology Sponsors: Global Pathology Laboratory Stiefel Laboratories Editors +BZ4(PUUMJFC %0 '0$00 Medicis 4UBOMFZ&4LPQJU %0 '"0$% CollaGenex +BNFT2%FM3PTTP %0 '"0$% Editorial Review Board 3POBME.JMMFS %0 JAOCD &VHFOF$POUF %0 Founding Sponsor &WBOHFMPT1PVMPT .% A0$%t&*MMJOPJTt,JSLTWJMMF .0 4UFQIFO1VSDFMM %0 t'"9 %BSSFM3JHFM .% wwwBPDEPSg 3PCFSU4DIXBS[F %0 COPYRIGHT AND PERMISSION: written permission must "OESFX)BOMZ .% be obtained from the Journal of the American Osteopathic College of Dermatology for copying or reprinting text of .JDIBFM4DPUU %0 more than half page, tables or figurFT Permissions are $JOEZ)PGGNBO %0 normally granted contingent upon similar permission from $IBSMFT)VHIFT %0 the author(s), inclusion of acknowledgement of the original source, and a payment of per page, table or figure of #JMM8BZ %0 reproduced matFSJBMPermission fees -
Communicable Disease Exclusion Guidelines for Schools and Child Care Settings
Deschutes County Health Services COMMUNICABLE DISEASE EXCLUSION GUIDELINES FOR SCHOOLS AND CHILD CARE SETTINGS Symptoms requiring exclusion of a child from school or childcare setting until either diagnosed and cleared by a licensed health care provider or recovery. FEVER: ANY fever greater than 100.5 F., may return when temperature decreases without use of fever-reducing medicine. VOMITTING: > 2 in the preceding 24 hours, unless determined to be from non-communicable conditions. May return when resolved. DIARRHEA: 3 or more watery or loose stools in 24 hours. May return when resolved for 24 hours. STIFF NECK: or headache with accompanying fever. May return after resolution of symptoms or diagnosis made and clearance given. RASHES: ANY new onset of rash if accompanied by fever; may return after rash resolves or if clearance given by health care providers. SKIN LESIONS: Drainage that cannot be contained within a bandage. JAUNDICE: Yellowing of eyes or skin. May return after diagnosis from physician and clearance given. BEHAVIOR CHANGE: Such as new onset of irritability, lethargy or somnolence. COUGH /SOB: Persistent cough with or without fever, serious sustained coughing, shortness of breath, or difficulty breathing. SYMPTOMS or complaints that prevent the student from active participation in usual school activities, or student requiring more care than the school staff can safely provide. Inform local county health department, (LHD), of all diseases listed as reportable. The local county health department should be consulted regarding any written communication that may be developed to inform parents/guardians about disease outbreaks, risk to students, families, and staff and/or control measures specific to an outbreak. -
Boils and Skin Infections Are Usually Caused by Bacteria
Communicable Diseases Factsheet Boils and skin infections are usually caused by bacteria. Avoid sharing items and wash hands thoroughly, especially after touching skin Boils and skin infections infections. Last updated: March 2017 What are boils? A boil (sometimes known as a furuncle) is an infection of the skin, often around a hair follicle. It is usually caused by Staphylococcus aureus bacteria (commonly known as golden staph). Many healthy people carry these bacteria on their skin or in their nose, but do not have any symptoms. Boils occur when bacteria get through broken skin and cause tender, swollen, pimple-like sores, which are full of pus. Boils usually get better on their own, but severe or recurring cases may require medical treatment and support. Staph bacteria may also cause other skin infections, including impetigo. Impetigo, commonly known as school sores (as they affect school-age children), are small blisters or flat crusty sores on the skin. See the Impetigo factsheet at http://www.health.nsw.gov.au/Infectious/factsheets/Pages/impetigo.aspx for specific information on Impetigo. How are they diagnosed? Most skin infections are diagnosed on the basis of their appearance and the presence of any related symptoms (such as fever). Your doctor may take swabs or samples from boils, wounds, or other sites of infection to identify the bacteria responsible. Some infections may be caused by bacteria that are resistant to some antibiotics. See the MRSA in the community factsheet for detailed information on infections caused by antibiotic -
Skin and Soft Tissue Infections Ohsuerin Bonura, MD, MCR Oregon Health & Science University Objectives
Difficult Skin and Soft tissue Infections OHSUErin Bonura, MD, MCR Oregon Health & Science University Objectives • Compare and contrast the epidemiology and clinical presentation of common skin and soft tissue diseases • State the management for skin and soft tissue infections OHSU• Differentiate true infection from infectious disease mimics of the skin Casey Casey is a 2 year old boy who presents with this rash. What is the best treatment? A. Soap and Water B. Ibuprofen, it will self OHSUresolve C. Dicloxacillin D. Mupirocin OHSUImpetigo Impetigo Epidemiology and Treatment OHSU Ellen Ellen is a 54 year old morbidly obese woman with DM, HTN and venous stasis who presented with a painful left leg and fever. She has had 3 episodes in the last 6 months. What do you recommend? A. Cefazolin followed by oral amoxicillin prophylaxis B. Vancomycin – this is likely OHSUMRSA C. Amoxicillin – this is likely erysipelas D. Clindamycin to cover staph and strep cellulitis Impetigo OHSUErysipelas Erysipelas Risk: lymphedema, stasis, obesity, paresis, DM, ETOH OHSURecurrence rate: 30% in 3 yrs Treatment: Penicillin Impetigo Erysipelas OHSUCellulitis Cellulitis • DEEPER than erysipelas • Microbiology: – 6-48hrs post op: think GAS… too early for staph (days in the making)! – Periorbital – Staph, Strep pneumoniae, GAS OHSU– Post Varicella - GAS – Skin popping – Staph + almost anything! Framework for Skin and Soft Tissue Infections (SSTIs) NONPurulent Purulent Necrotizing/Cellulitis/Erysipelas Furuncle/Carbuncle/Abscess Severe Moderate Mild Severe Moderate Mild I&D I&D I&D I&D IV Rx Oral Rx C&S C&S C&S C&S Vanc + Pip-tazo OHSUEmpiric IV Empiric MRSA Oral MRSA TMP/SMX Doxy What Are Your “Go-To” Oral Options For Non-Purulent SSTI? Amoxicillin Doxycycline OHSUCephalexin Doxycycline Trimethoprim-Sulfamethoxazole OHSU Miller LG, et al. -
Reportable Disease Surveillance in Virginia, 2013
Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1 -
Viability of Methicillin-Resistant Staphylococcus Aureus on Artificial Turf Under
Viability of Methicillin-Resistant Staphylococcus aureus on Artificial Turf Under Outdoor and Laboratory Environmental Conditions A thesis presented to the faculty of the College of Health Sciences and Professions of Ohio University In partial fulfillment of the requirements for the degree Master of Science Ashley N. Hardbarger June 2012 © 2012 Ashley N. Hardbarger. All Rights Reserved. 2 This thesis titled Viability of Methicillin-Resistant Staphylococcus aureus on Artificial Turf Under Outdoor and Laboratory Environmental Conditions by ASHLEY N. HARDBARGER has been approved for the School of Applied Health Sciences and Wellness and the College of Health Sciences and Professions by Andrew Krause Assistant Professor of Applied Health Sciences and Wellness Randy Leite Dean, College of Health Sciences and Professions 3 ABSTRACT HARDBARGER, ASHLEY N., M.S., June 2012, Athletic Training Viability of Methicillin-Resistant Staphylococcus Aureus on Artificial Turf Under Outdoor and Laboratory Environmental Conditions Director of Thesis: Andrew Krause Methicillin-resistant Staphylococcus aureus has survived on artificial turf in a laboratory setting when provided a nutrient source. There is limited evidence on the viability of MRSA in outdoor environmental conditions. This study compared the survival of MRSA in a laboratory environment to an outdoor environment over seven days. Artificial turf was inoculated with MRSA strain USA300 and exposed to laboratory and outdoor environmental settings. Samples were collected daily. MRSA survival was determined by growth on CHROMagar plates. Results indicated a difference in the mean survival time of MRSA between a laboratory environment (7.00 ± 0.00 days) and an outdoor environment (4.67 ± 2.52). Conditions including surface temperature, ambient temperature, relative humidity, precipitation and solar radiation may have affected MRSA survival. -
New Jersey Chapter American College of Physicians
NEW JERSEY CHAPTER AMERICAN COLLEGE OF PHYSICIANS ASSOCIATES ABSTRACT COMPETITION 2015 SUBMISSIONS 2015 Resident/Fellow Abstracts 1 1. ID CATEGORY NAME ADDITIONAL PROGRAM ABSTRACT AUTHORS 2. 295 Clinical Abed, Kareem Viren Vankawala MD Atlanticare Intrapulmonary Arteriovenous Malformation causing Recurrent Cerebral Emboli Vignette FACC; Qi Sun MD Regional Medical Ischemic strokes are mainly due to cardioembolic occlusion of small vessels, as well as large vessel thromboemboli. We describe a Center case of intrapulmonary A-V shunt as the etiology of an acute ischemic event. A 63 year old male with a past history of (Dominik supraventricular tachycardia and recurrent deep vein thrombosis; who has been non-compliant on Rivaroxaban, presents with Zampino) pleuritic chest pain and was found to have a right lower lobe pulmonary embolus. The deep vein thrombosis and pulmonary embolus were not significant enough to warrant ultrasound-enhanced thrombolysis by Ekosonic EndoWave Infusion Catheter System, and the patient was subsequently restarted on Rivaroxaban and discharged. The patient presented five days later with left arm tightness and was found to have multiple areas of punctuate infarction of both cerebellar hemispheres, more confluent within the right frontal lobe. Of note he was compliant at this time with Rivaroxaban. The patient was started on unfractionated heparin drip and subsequently admitted. On admission, his vital signs showed a blood pressure of 138/93, heart rate 65 bpm, and respiratory rate 16. Cardiopulmonary examination revealed regular rate and rhythm, without murmurs, rubs or gallops and his lungs were clear to auscultation. Neurologic examination revealed intact cranial nerves, preserved strength in all extremities, mild dysmetria in the left upper extremity and an NIH score of 1. -
Medicine Safety “Pharmacovigilance” Fact Sheet
MINISTRY OF MEDICAL SERVICES MINISTRY OF PUBLIC HEALTH AND SANITATION PHARMACY AND POISONS BOARD MEDICINE SAFETY “PHARMACOVIGILANCE” FACT SHEET What is medicine safety? Medicine safety, also referred to as Pharmacovigilance refers to the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of medicines, biological products, herbals and traditional medicines. It aims at identifying new information about hazards, and preventing harm to patients. What is an Adverse Drug Reaction? The World Health Organization defines an adverse drug reaction (ADR) as "A response to a drug which is noxious and unintended, and which occurs at doses normally used or tested in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function". Simply put, when the doctor prescribes you medicines, he expects the desirable effects of them. The undesired effects of the medicines is the ADR or, commonly known as “side effects”. An adverse drug reaction is considered to be serious when it is suspected of causing death, poses danger to life, results in admission to hospital, prolongs hospitalization, leads to absence from productive activity, increased investigational or treatment costs, or birth defects. Age, gender, previous history of allergy or reaction, race and genetic factors, multiple medicine therapy and presence of concomitant disease processes may predispose one to adverse effects. Why monitor adverse drug reactions? Before registration and marketing of a medicine, its safety and efficacy experience is based primarily on clinical trials. Some important adverse reactions may not be detected early or may even be rare. -
AVANDIA (Rosiglitazone Maleate Tablets), for Oral Use Ischemic Cardiovascular (CV) Events Relative to Placebo, Not Confirmed in Initial U.S
HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include all the information needed to use • Fluid retention, which may exacerbate or lead to heart failure, may occur. AVANDIA safely and effectively. See full prescribing information for Combination use with insulin and use in congestive heart failure NYHA AVANDIA. Class I and II may increase risk of other cardiovascular effects. (5.1) • Meta-analysis of 52 mostly short-term trials suggested a potential risk of AVANDIA (rosiglitazone maleate tablets), for oral use ischemic cardiovascular (CV) events relative to placebo, not confirmed in Initial U.S. Approval: 1999 a long-term CV outcome trial versus metformin or sulfonylurea. (5.2) • Dose-related edema (5.3) and weight gain (5.4) may occur. WARNING: CONGESTIVE HEART FAILURE • Measure liver enzymes prior to initiation and periodically thereafter. Do See full prescribing information for complete boxed warning. not initiate therapy in patients with increased baseline liver enzyme levels ● Thiazolidinediones, including rosiglitazone, cause or exacerbate (ALT >2.5X upper limit of normal). Discontinue therapy if ALT levels congestive heart failure in some patients (5.1). After initiation of remain >3X the upper limit of normal or if jaundice is observed. (5.5) AVANDIA, and after dose increases, observe patients carefully for signs • Macular edema has been reported. (5.6) and symptoms of heart failure (including excessive, rapid weight gain; • Increased incidence of bone fracture was observed in long-term trials. dyspnea; and/or edema). If these signs and symptoms develop, the heart (5.7) failure should be managed according to current standards of care. -
Pharmaceutical Sales Representatives
[Chapter 4, 28 April] Chapter 4 Pharmaceutical sales representatives Andy Gray, Jerome Hoffman and Peter R Mansfield The presence of pharmaceutical industry sales representatives almost seems a fact of life at many modern medical centres and universities around the world. Many medical and pharmacy students come into contact with pharmaceutical industry sales representatives during their training. Later on in the careers of many health professionals, encounters with sales representatives can occur on a daily basis, taking up a substantial portion of a busy health professional s time. However, health professionals have a choice in the matter - they may choose not to see pharmaceutical sales representatives at all or they may attempt to manage such interactions.’ This chapter aims to provide information to help you make up your own mind on this issue. This choice has important consequences for health professionals practice and patients, so requires careful consideration. ’ Aims of this chapter By the end of the session based on this chapter, you should be able to answer a series of questions on your interactions with sales representatives: In what ways, if any, might I hope to benefit from meeting with sales representatives? How are sales representatives selected, trained, supported and managed? What information do sales representatives provide? How might contact with sales representatives influence me in a positive or negative way? Should I have contact with sales representatives at all? Is it possible, if I choose to have contact with sales representatives, to minimise the potential harm and maximise the potential benefit for my professional development and practice? This chapter presents evidence that we believe can be helpful in addressing these questions, and ends with a series of activities that will allow students to work on the issue in more depth. -
Alison Bass Curriculum Vitae Current Affiliations • Associate Professor Of
Alison Bass Curriculum Vitae Current Affiliations Associate Professor of Journalism, West Virginia University 2012-present Author, Freelance Writer and Blogger 2008-present Journalism Experience Author of forthcoming book, Getting Screwed: Sex Workers and the Law (Fall 2015) Getting Screwed takes a wide-ranging historic look at prostitution in the United States. It weaves the true stories of sex workers (past and present) together with the latest research in exploring the advisability of decriminalizing adult prostitution. To read more about this project, visit www.sexworkandthelaw.com/. Author of Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial Side Effects won the NASW Science in Society Award and garnered critical acclaim from many quarters, including The New York Review of Books, The Boston Globe and The Washington Post. Published by Algonquin Books in 2008, Side Effects tells the true story of three people who exposed the deception behind the making of a bestselling drug. To read more about the book, visit www.alison-bass.com. Journalist-Blogger 2008-present My blog, at http://www.sexworkandthelaw.com/blog/ is an ongoing discussion about sex work and public health. I have also written blogs for The Huffington Post and opinion pieces for The Boston Globe about various topics including scientific misconduct and sex work. Alicia Patterson Foundation 2007-2008 Won a prestigious Alicia Patterson Fellowship to write Side Effects, a book about scientific fraud and conflicts of interest in the medical/pharmaceutical industry. CIO magazine, Executive Editor 2000-2006 Wrote and edited feature-length articles and columns for CIO, an award-winning business magazine that covers information technology. -
What Is Fungal Acne, Exactly?
If you’re dealing with angry red bumps on your skin, your first thought (understandably) probably jumps to acne. But what if you’ve tried absolutely everything—a salicylic acid face wash, benzoyl peroxide spot treatment, or other common OTC acne products—and they’re just not fading away? First, take a closer look at the spots. If you have inflamed, chicken skin-like bumps rather than your usual speckling of swollen pimples, you may actually be dealing with “fungal acne”—which technically isn’t like your normal acne at all. Fungal acne is common during the warmer, humid months, making now the prime time to develop those little bumps across your hairline, jawline, butt, chest, and back—pretty much anywhere on your body. “I’ve been seeing it a lot in the office lately,” says Doris Day, M.D., a board-certified dermatologist at Advanced Dermatology and Aesthetics in New York City. Here’s exactly how to differentiate fungal acne from your traditional breakout—and what you can do to get rid of it ASAP. What is fungal acne, exactly? First, a little acne 101: Your skin has tiny pores and, under normal circumstances, dead skin cells rise to the surface of the pore, where your body sheds them, according to the American Academy of Dermatology (AAD). But when your body starts to produce a lot of sebum (a.k.a. oil), those dead skin cells can stick together inside your pore and become clogged. Hello, pimple. Most commonly, bacteria that lives on your skin, called P. acnes, gets trapped inside the clogged pore and causes inflammation in what’s known as bacterial acne, the AAD says.